Advertisement

Topics

Latest "Acticor Biotech" News Stories

07:43 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Acticor Biotech" found in our extensive news archives from over 250 global news sources.

More Information about Acticor Biotech on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Acticor Biotech for you to read. Along with our medical data and news we also list Acticor Biotech Clinical Trials, which are updated daily. BioPortfolio also has a large database of Acticor Biotech Companies for you to search.

Showing "Acticor Biotech" News Articles 1–25 of 5,800+

Extremely Relevant

Acticor raises €1.7mm through undisclosed round

Acticor Biotech SAS (mAb therapeutics to treat ischemic stroke) completed a €1.7mm ($2mm) undisclosed round from Primer Cap...


Stroke-focused Acticor closes €590k seed round

Ischemic stroke-focused start-up Acticor Biotech SAS (developing a monoclonal antibody with antiplatelet activity) raised €...

Acticor Biotech Appoints Dr Andrea Comenducci as Medical Director

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombo-embolic diseases, including stroke and pulmonary embolism, today announced the appointment of Dr Andrea Comenducci MD as Medical Director in charge of clinical R&D and medical affairs. Dr Comenducci specialises in the cardiovascular field, and his priority ...


French Acticor Biotech raises €15.3m

Relevant

Acticor closes €15.3mm Series B round; could get another €5mm

Acticor Biotech SAS (antibody therapeutics for acute thrombotic diseases, including ischemic stroke and pulmonary embolism) c...

Biotronik secures FDA approval for Acticor and Rivacor CRM device families

Biotronik said the Acticor and Rivacor systems are designed to incorporate more diagnostic and therapeutic capabilities in smaller devices with extended battery longevity. The six new tachycardia solutions The post Biotronik secures FDA approval for Acticor and Rivacor CRM device families appeared first on Compelo Medical Devices - Latest industry news and analysis.

Acticor early round raises €1.4mm; later adds on €1.5mm

Acticor Biotech SAS (MAb therapeutics to treat ischemic stroke) completed an undisclosed €1.4mm ($1.55mm) capital increase ...

Acticor Biotech Raises €15.3M In a Series B Financing

New financing will enable the company to launch shortly the first Phase II clinical trial of its lead candidate ACT017 inhibiting GPVI in acute ischemic stroke Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and pulmonary embolism, today announced that it has completed a €15...

FDA OKs Biotronik's high-voltage tachycardia devices

The FDA has granted Biotronik premarket approval for its Rivacor and Acticor families of high-voltage cardiac rhythm-managem -More- 

Acticor Biotech SAS Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryActicor Biotech SAS Acticor, a subsidiary of MabDesign is a biopharmaceutical company that develops innovative therapeutic strategy for the emergency treatment of ischemic strokes. The company provides Fab product that provides monoclonal antibody targeting solutions through platelet glycoprotein VI, which is a protein cloned in the INSERM unit U1148. Its Fab finds application in the area o...

What Does the Largest Biotech IPO Ever Mean for European Biotech?

With a massive €530M ($604M) raised, US-based Moderna has made a record biotech IPO. The news could give a significant boost to developers of messenger RNA, a technology that is still several years away from the market. Entering the Nasdaq ... The post What Does the Largest Biotech IPO Ever Mean for European Biotech? appeared first on Labiotech.eu.

Biotech-Dividendenperle BB Biotech: Was Investoren zur Generalversammlung wissen sollten!

Bei BB Biotech (WKN: A0NFN3) war es diese Woche so weit! Die Generalversammlung tagte und hat - so wie wir derzeit lesen können - alles durchgewinkt, was das Management der auf Biotech-Perlen spezi...

VIDEO: Biotech Showcase 2019: F2G Accelerates Phase IIb Program Vs Life-Threatening Fungal Infections

Ian Nicholson, CEO of F2G, updated Mike Ward during Biotech Showcase 2019 on the progress the biotech company is having...   

PCI Biotech Holding ASA: PCI Biotech: Disclosure of voting rights for Chairman of the Board

Oslo, 13 September 2018. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and ...

VIDEO: Biotech Showcase 2019: Rexgenero Advances CLI-Focused Regenerative Medicine Into Phase III

Joe Dupere, CEO at Rexgenero, reveals to Mike Ward during Biotech Showcase 2019 the four-year-old UK biotech’s plans.    

FIT Biotech Oy: Changes in FIT Biotech’s Board of Directors

FIT Biotech Oy Company release 7.1.2019 at 9:55 EET Changes in FIT Biotech’s Board of Directors FIT Biotech Oy’s (“Company”, FITBIO: FN Finland) Chairman of the Board of Directors, Doctor Chitra Bharucha has resigned from Board of Directors for medical reasons. … Continue reading →

Are Recent IPO Delays Bad News for European Biotech?

Over the last two weeks, several biotech companies in Europe have decided to postpone IPOs on the stock markets — is this a sign that biotech stocks are underperforming?   Since the end of October, several European biotech companies have ... The post Are Recent IPO Delays Bad News for European Biotech? appeared first on Labiotech.eu.

The Top 10 Biotech Companies in Stockholm

As Sweden’s capital, Stockholm is perhaps best known for its picturesque islands and bridges, crayfish festivals, and wondrously preserved medieval architecture, but the city is also a hub of biotech enterprise. Stockholm’s biotech industry is particularly strong when it comes ... The post The Top 10 Biotech Companies in Stockholm appeared first on Labiotech.eu.

Strict regulations hamper biotech farm animal product consumption

Scientists at the University of California at Davis are developing biotech cattle that do not grow horns and biotech cows tha -More- 

Accelerator or Incubator? What to Look for in a Biotech Startup Program

Early stage biotech companies and scientists interested in commercialization need great accelerator programs, not more biotech incubators. Biotech companies and scientists who start out on the road to commercialization may need an accelerator to bring out the entrepreneurial spirit. The incubator and accelerator models are conflated all the time in biotech, much to the fury […] The post Acce...

LISTEN: Fake friends at the FDA, cancer counter-narratives, and biotech’s bear turn

Is the next big idea in oncology a bust? What does "successful" mean, exactly? And why does Wall Street hate biotech all of a sudden? Find out on our biotech…

7 Tips for Biotech Companies Seeking Capital in a Volatile Market

Last year was a remarkable year for biotech companies going public. Not only did an unusually large number of biotech companies go public, but a significant number of early-stage biotech companies went public at premium valuations relative to their later-clinical stage peers. There were approximately 58 biotech IPOs in 2018 (excluding offerings with under $25 […]

Last Chance to Save on Tickets for Xconomy’s Bay Area Biotech Event

There’s just one week left until Xconomy’s latest biotech event, “San Francisco Biotech: The Next Generation.” Don’t let the clock run out while you can still save some cash on a ticket. Next Wednesday, Dec. 5, company founders and visionary scientists will share how they are pursuing new ideas and breaking biotech boundaries. Don’t wait […]

STAT Plus: What to watch in biotech at the JPM Healthcare Conference and beyond in 2019

A STAT-curated preview of biotech events and issues that we believe will grab headlines and attention in biotech over the next 12 months.

Biotech Sector Raises $23bn In Venture Capital In 2018

While major biotech indices went south in 2018, VC enthusiasm for biotech remained bullish. Biotech companies raised a record $22.83bn...  


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks